Adicet Bio (ACET) AI Stock Analysis

• Market Cap: $51.74M
• Dividend Yield: N/A
• Average Volume (3M): 457.52K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.80
• Revenue Growth: N/A
• EPS Growth: 59.75%
• Country: US
• Employees: 152
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): -0.31
• Shares Outstanding: 82,709,625
• 10 Day Avg. Volume: 381,558
• 30 Day Avg. Volume: 457,525
• PEG Ratio: 0.30
• Price to Book (P/B): -1.54
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.97
• Enterprise Value/Market Cap: 2.52
• Enterprise Value/Revenue: 5.07
• Enterprise Value/Gross Profit: -81.54
• Enterprise Value/Ebitda: -0.28
• 1Y Price Target: $5.67
• Price Target Upside: 829.51% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 27 Underperform
• Price Target: ―

Adicet Bio faces significant financial challenges and technical weaknesses, with no revenue and ongoing losses as critical concerns. The poor valuation further impacts the stock's appeal. While the new board appointment is positive, it does not mitigate the substantial risks present in the company’s financials and market performance.

Positive Factors

Financial Stability

Management expects a cash runway into the second half of 2026, indicating financial stability.

Innovative Strategy

Adicet Bio's approach targets CD20, which is different from the majority of peer cell therapy programs that target CD19, showcasing its unique strategy.

Regulatory Advancement

Adicet Bio received Fast Track Designation for ADI-001 for refractory SLE with extrarenal involvement and systemic sclerosis.

Negative Factors

Data Delays

The initial data from two Phase 1 programs have been delayed to the second half of the year to provide more comprehensive follow-up information.

Safety Concerns

Safety remains an ongoing concern from Phase 1a that reported 2 DLTs at DL2 (80mn cells), autoimmune hepatitis and cardiogenic shock.

Valuation Uncertainty

Initial data from the immunology and solid tumor programs are not yet included in valuation models, as data from Adicet and peers are still awaited.

Adicet Bio Business Overview & Revenue Model

Company Description

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.

How the Company Makes Money

Adicet Bio primarily makes money through the development and commercialization of its allogeneic gamma delta T cell therapies for cancer treatment. The company generates revenue from partnerships and collaborations with other pharmaceutical companies, as well as through grants and funding aimed at advancing its research and development efforts. Additionally, Adicet Bio may earn income from licensing agreements, where it allows other companies to utilize its proprietary technology in exchange for upfront payments, milestone payments, and potential royalties on future products. The success of these revenue streams is significantly influenced by the company's ability to bring its therapeutic candidates to market and establish strong industry collaborations.

Adicet Bio Financial Statement Overview

Summary

Adicet Bio's financial performance is weak, with no revenue generation, ongoing losses, and negative cash flow. This points to significant operational and financial challenges despite a strong cash position.

Income Statement

Adicet Bio's income statement reflects significant challenges with no total revenue reported in the recent year, leading to a gross profit margin of 0%. The consistent net losses over the years and a declining EBIT indicate ongoing operational inefficiencies. The company has not shown recent revenue growth, presenting a concerning outlook for profitability.

Balance Sheet

The balance sheet shows some stability with a healthy equity position due to a positive stockholders' equity. However, the company carries a debt level that is notable, though it's offset by a substantial cash position. Despite these factors, the equity ratio suggests some financial risk due to high liabilities compared to assets.

Cash Flow

The cash flow statement highlights negative operating cash flow and free cash flow, indicating cash outflows from operations. The free cash flow growth rate is negative, and the operating cash flow to net income ratio is unfavorable, reflecting cash management issues. The reliance on financing activities to cover deficits is a potential area of concern.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	24.99M	9.73M	17.90M
Gross Profit	-1.60M	0.00	-6.10M	19.98M	9.73M	17.90M
EBITDA	-114.17M	-110.65M	-136.53M	-64.70M	-60.41M	-37.41M
Net Income	-117.32M	-117.12M	-142.66M	-67.03M	-62.00M	-36.68M
Balance Sheet
Total Assets	191.27M	220.22M	207.29M	330.69M	338.94M	153.84M
Cash, Cash Equivalents and Short-Term Investments	150.44M	176.30M	159.71M	257.66M	277.54M	94.61M
Total Debt	16.25M	17.23M	20.92M	21.02M	20.94M	21.64M
Total Liabilities	29.82M	33.61M	37.12M	38.35M	35.81M	44.01M
Stockholders Equity	161.45M	186.61M	170.18M	-238.11M	-168.32M	-106.33M
Cash Flow
Free Cash Flow	-97.30M	-93.50M	-98.18M	-61.55M	-64.10M	-42.54M
Operating Cash Flow	-94.93M	-92.38M	-93.72M	-44.77M	-51.05M	-41.55M
Investing Cash Flow	-121.86M	-119.24M	-4.46M	-16.78M	-2.80M	115.22M
Financing Cash Flow	237.00K	111.31M	236.00K	41.51M	242.69M	303.00K

Adicet Bio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.61
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACET, the sentiment is Negative. The current price of 0.61 is below the 20-day moving average (MA) of 0.72, below the 50-day MA of 0.67, and below the 200-day MA of 0.96, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 40.28 is Neutral, neither overbought nor oversold. The STOCH value of 14.35 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ACET.

Adicet Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTMX	66 Neutral	$354.47M	4.54	-58.97%	―	23.81%	146.45%
Sector *	51 Neutral	$7.41B	0.36	-61.88%	2.33%	17.09%	1.64%
BLUE	51 Neutral	$48.67M	―	-546.55%	―	127.51%	56.94%
IKNA	41 Neutral	$65.63M	―	-30.49%	―	-100.00%	37.59%
DTIL	41 Neutral	$47.68M	2.40	-50.81%	―	-11.11%	79.74%
ACRV	36 Underperform	$37.63M	―	-62.41%	―	―	10.84%
ACET	27 Underperform	$51.74M	―	-55.83%	―	―	59.75%

Adicet Bio Corporate Events

Adicet Bio Appoints Michael Grissinger to Board

On April 17, 2025, Adicet Bio announced the appointment of Michael Grissinger to its Board of Directors. Grissinger, with over four decades of experience in pharmaceutical business development and strategic transactions, is expected to bring valuable insights to Adicet as it advances its gamma delta T cell platform. His extensive background, particularly in immunology, will be instrumental in guiding the company’s growth and development of therapies for autoimmune and solid tumor indications.

Spark’s Take on ACET Stock

According to Spark, TipRanks’ AI Analyst, ACET is a Underperform.

Adicet Bio faces significant financial challenges with no revenue and consistent losses, presenting major risk factors. The technical analysis suggests a bearish trend, while poor valuation due to a negative P/E ratio further impacts the stock’s attractiveness. Without improvement in revenue and cash flow management, the outlook remains concerning.

To see Spark’s full report on ACET stock, click here.